Dr. Nirav Niranjan Shah explains the data behind why autologous stem cell transplant should remain the standard of care for patients with relapsed chemo-sensitive DLBCL.
Nirav Niranjan Shah, MD
Advertisement
Articles by Nirav Niranjan Shah, MD
Advertisement
Latest Updated Articles
Autologous Stem Cell Transplant Should Remain Standard of Care for Certain DLBCL Patients, Expert SaysPublished: June 9th 2020 | Updated:
Advertisement
Advertisement
Trending on CURE
1
Chronic Myeloid Leukemia: From Diagnosis to Ongoing Management
2
Understanding the Role of Artificial Intelligence in Gastrointestinal Cancer Care
3
Given Months to Live, She’s Now a Five-Year Glioblastoma Survivor
4
Highlighting Real-World Data on Immunotherapy Use in Advanced Gastric Cancer
5